FDA approves the first Tysabri biosimilar for MS and Crohn’s disease
The Sandoz biosimilar, Tyruko, was approved by the US FDA for all labelled indications of Tysabri based on Phase I and III data.
The Sandoz biosimilar, Tyruko, was approved by the US FDA for all labelled indications of Tysabri based on Phase I and III data.
What's Your Reaction?
